Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.840
-0.120 (-2.42%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Bolt Biotherapeutics Revenue
In the year 2025, Bolt Biotherapeutics had annual revenue of $7.70M with 0.07% growth. Bolt Biotherapeutics had revenue of $2.50M in the quarter ending December 31, 2025.
Revenue (ttm)
$7.70M
Revenue Growth
+0.07%
P/S Ratio
1.22
Revenue / Employee
$334,565
Employees
23
Market Cap
9.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 5.00K | 0.07% |
| Dec 31, 2024 | 7.69M | -186.00K | -2.36% |
| Dec 31, 2023 | 7.88M | 2.15M | 37.48% |
| Dec 31, 2022 | 5.73M | 4.47M | 354.68% |
| Dec 31, 2021 | 1.26M | 1.03M | 445.45% |
| Dec 31, 2020 | 231.00K | 16.00K | 7.44% |
| Dec 31, 2019 | 215.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBOLT News
- 6 weeks ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Bolt Biotherapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 5 months ago - Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
- 9 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Bolt Biotherapeutics Transcript: Status Update - Transcripts
- 1 year ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire